NCT00234026View on ClinicalTrials.gov

Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2005

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Lymphoma
Interventions
DRUG

gemcitabine hydrochloride

Trial Locations (16)

5001

Kantonspital Aarau, Aarau

5404

Baden

6500

Oncology Institute of Southern Switzerland, Bellinzona

8001

Zurich

8002

Onkozentrum - Klinik im Park, Zurich

8063

City Hospital Triemli, Zurich

8610

Spital Uster, Uster

8952

Spital Limmattal, Schlieren

CH-5404

Kantonsspital Baden, Baden

CH-8180

Spital Buelach, Bülach

CH-9007

Kantonsspital - St. Gallen, Sankt Gallen

CH-8400

Kantonsspital Winterthur, Winterthur

CH-8008

Klinik Hirslanden, Zurich

CH-8037

Stadtspital Waid, Zurich

CH-8044

Zurich

CH-8091

UniversitaetsSpital Zuerich, Zurich

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT00234026 - Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter